PL3444268T3 - Leukocydyny staphylococcus aureus, kompozycje terapeutyczne i ich zastosowania - Google Patents

Leukocydyny staphylococcus aureus, kompozycje terapeutyczne i ich zastosowania

Info

Publication number: PL3444268T3
Authority: PL; Poland
Prior art keywords: leucocidines; applications; staphylococcus aureus; therapeutic compositions; therapeutic
Prior art date: 2010-05-05

Application number

PL18196549T

Other languages

English (en)

Inventor

Victor J Torres

Ashley L DUMONT

Original Assignee

New York University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-05-05

Filing date

2011-05-05

Publication date

2022-04-19

2011-05-05 Application filed by New York University filed Critical New York University

2022-04-19 Publication of PL3444268T3 publication Critical patent/PL3444268T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
- G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
Epidemiology (AREA)
Zoology (AREA)
Food Science & Technology (AREA)
Cell Biology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Tropical Medicine & Parasitology (AREA)
Toxicology (AREA)
Wood Science & Technology (AREA)
Virology (AREA)
Dermatology (AREA)

PL18196549T 2010-05-05 2011-05-05 Leukocydyny staphylococcus aureus, kompozycje terapeutyczne i ich zastosowania PL3444268T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US33155010P	2010-05-05	2010-05-05
EP16187485.4A EP3121191B1 (en)	2010-05-05	2011-05-05	Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
EP18196549.2A EP3444268B1 (en)	2010-05-05	2011-05-05	Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
PCT/US2011/035354 WO2011140337A2 (en)	2010-05-05	2011-05-05	Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
EP11778343.1A EP2566519B1 (en)	2010-05-05	2011-05-05	Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof

Publications (1)

Publication Number	Publication Date
PL3444268T3 true PL3444268T3 (pl)	2022-04-19

Family

ID=44902083

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL18196549T PL3444268T3 (pl)	2010-05-05	2011-05-05	Leukocydyny staphylococcus aureus, kompozycje terapeutyczne i ich zastosowania

Country Status (21)

Country	Link
US (5)	US9783582B2 (pl)
EP (4)	EP4015523A1 (pl)
JP (4)	JP6031029B2 (pl)
KR (3)	KR102050078B1 (pl)
CN (2)	CN103025352B (pl)
AU (5)	AU2011247989C1 (pl)
BR (1)	BR112012029521A2 (pl)
CA (2)	CA3088918A1 (pl)
DK (1)	DK3444268T3 (pl)
ES (2)	ES2605476T3 (pl)
HR (1)	HRP20220068T1 (pl)
HU (1)	HUE058787T2 (pl)
IL (2)	IL274109B2 (pl)
LT (1)	LT3444268T (pl)
MX (4)	MX2012012859A (pl)
MY (1)	MY165618A (pl)
PL (1)	PL3444268T3 (pl)
RU (2)	RU2677140C1 (pl)
SI (1)	SI3444268T1 (pl)
WO (1)	WO2011140337A2 (pl)
ZA (4)	ZA201208455B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP4015523A1 (en)	2010-05-05	2022-06-22	New York University	Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
NZ764564A (en) *	2011-06-19	2022-10-28	Univ New York	Methods of treating and preventing staphylococcus aureus infections and associated conditions
NZ700578A (en)	2012-04-17	2017-03-31	Arsanis Biosciences Gmbh	Cross-reactive staphylococcus aureus antibody
US9657103B2 (en)	2012-05-02	2017-05-23	New York University	Methods of treating and preventing Staphylococcus aureus infections and associated conditions
KR101826538B1 (ko) *	2012-05-30	2018-02-07	현대자동차 주식회사	차량용 글래스 몰딩 부착 장치 및 그 방법
WO2014187746A2 (en)	2013-05-21	2014-11-27	Arsanis Biosciences Gmbh	Generation of highly potent antibodies neutralizing the lukgh (lukab) toxin of staphylococcus aureus
CN110420316A (zh)	2013-06-18	2019-11-08	纽约大学	参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素：新型治疗靶点
RU2016119052A3 (en) *	2013-10-17	2018-09-10	Arsanis Biosciences Gmbh	Cross-reactive Staphylococcus aureus antibody sequences
CA2932819A1 (en)	2013-12-09	2015-06-18	New York University	Compositions and methods for phagocyte delivery of anti-staphylococcal agents
MX2016007212A (es) *	2013-12-19	2016-09-07	Arsanis Biosciences Gmbh	Anticuerpos dirigidos contra la toxina lukgh (lukab) de staphylococcus aureus y secuencias de anticuerpos.
JP2018517708A (ja) *	2015-06-05	2018-07-05	ニューヨーク・ユニバーシティ	抗ブドウ球菌生物学的薬剤のための組成物及び方法
EP3592770A4 (en)	2017-03-06	2020-12-16	Vanderbilt University	HUMAN MONOCLONAL ANTIBODIES DIRECTED AGAINST STAPHYLOCOCCUS AUREUS LUKAB TOXIN
EP3638286A4 (en) *	2017-06-13	2021-03-10	Integrated Biotherapeutic Vaccines, Inc.	IMMUNOGENIC COMPOSITIONS CONTAINING POLYPEPTIDES DERIVED FROM LEUCOCIDINS LUKA AND LUKB OF STAPHYLOCOCCUS AUREUS
KR102061735B1 (ko) *	2018-06-08	2020-01-02	대한민국(농림축산식품부 농림축산검역본부장)	황색포도알균 약독화 장독소 및 세포독소 재조합 단백질을 포함하는 백신 조성물
US20220241390A1 (en) *	2018-06-08	2022-08-04	Republic Of Korea (Animal And Plant Quarantine Agency)	Vaccine composition comprising recombinant protein of staphylococcus aureus attenuated enterotoxin and cytotoxin
JP7525471B2 (ja)	2018-07-24	2024-07-30	メディミューン，エルエルシー	Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体
BR112021006622A2 (pt)	2018-10-09	2021-07-20	Medimmune, Llc	combinações de anticorpos anti-staphylococcus aureus
TWI895248B (zh)	2018-10-09	2025-09-01	美商麥迪紐有限責任公司	針對金黃色葡萄球菌白血球毒素的抗體
US12514914B2 (en)	2019-05-14	2026-01-06	The University Of Chicago	Methods and compositions comprising Staphylococcus protein a (SpA) variants
JP2022550884A (ja) *	2019-10-02	2022-12-05	ヤンセンファッシンズアンドプリベンションベーフェー	スタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）ペプチドおよび使用方法
WO2022067255A2 (en) *	2020-09-28	2022-03-31	Janssen Pharmaceuticals, Inc.	Variant staphylococcus aureus luka and lukb polypeptides and vaccine compositions
CA3215751A1 (en) *	2021-04-02	2022-10-06	Janssen Pharmaceuticals, Inc.	Staphylococcus aureus vaccine compositions
ES3002583A1 (es) *	2023-09-05	2025-03-07	Lopez Juan Luis Recio	Procedimiento de procesamiento de muestras biologicas para inmunoensayos

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US400A (en)		1837-09-25		Mode of causing puppet valves to work lights
US300A (en)		1837-07-29		Machine foe spinning woolen roving
RU2122862C1 (ru) *	1995-12-08	1998-12-10	Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова	Бесклеточная антистафилококковая вакцина для лечения хронической стафилококковой инфекции
ES2321892T3 (es)	1998-09-14	2009-06-12	Nabi Biopharmaceuticals	Composiciones de beta-glucanos e inmunoglobulinas especificas.
CA2404260A1 (en)	2000-03-21	2001-09-27	Elitra Pharmaceuticals, Inc.	Identification of essential genes in prokaryotes
US6849259B2 (en)	2000-06-16	2005-02-01	Symphogen A/S	Polyclonal antibody composition for treating allergy
AT410798B (de) *	2001-01-26	2003-07-25	Cistem Biotechnologies Gmbh	Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) *	2001-03-27	2001-05-16	Chiron Spa	Staphylococcus aureus
ES2421134T3 (es)	2002-05-03	2013-08-29	Massachusetts Institute Of Technology	delta 4,5 Glicuronidasa y usos de la misma
TWI374892B (en)	2005-06-13	2012-10-21	Glaxosmithkline Biolog Sa	Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
CN100485038C (zh) *	2005-09-13	2009-05-06	四川大学华西医院	小型化抗耐药金黄色葡萄球菌多肽及其应用与制备方法
EP1996231A4 (en) *	2006-02-22	2010-09-15	Texas A & M Univ Sys	ANTIBODIES WITH STRONG EXPRESSED PUTATIVE ANTIGEN DETECTION OF CA-MRSA AND METHOD OF USE
US20080131457A1 (en) *	2006-06-12	2008-06-05	Nabi Biopharmaceuticals	Use of alpha-toxin for treating and preventing staphylococcus infections
CN101535811B (zh) *	2006-10-18	2016-05-04	生物梅里埃公司	用于体外诊断产pvl金黄色葡萄球菌的方法
GB0624340D0 (en) *	2006-12-06	2007-01-17	Nature Therapeutics Ltd	Antimicrobial composition
JP5658564B2 (ja) *	2007-08-31	2015-01-28	ザ・ユニバーシティ・オブ・シカゴＴｈｅＵｎｉｖｅｒｓｉｔｙＯｆＣｈｉｃａｇｏ	ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
JP2011500036A (ja)	2007-10-15	2011-01-06	ザユニバーシティーオブクイーンズランド	構築物系およびその使用
CN101182350A (zh) *	2007-11-02	2008-05-21	山东省农业科学院奶牛研究中心	金黄色葡萄球菌α-溶血素及其编码序列
WO2009111177A2 (en) *	2008-03-05	2009-09-11	Mount Sinai School Of Medicine Of New York University	Compositions and methods comprising genetically enhanced obligate and facultative anaerobic bacteria for oncopathic cancer therapy
EP2291196A4 (en)	2008-05-12	2012-05-30	Strox Biopharmaceuticals Llc	FOR STAPHYLOCOCCUS AUREUS SPECIFIC ANTIBODY PREPARATIONS
JP2012500855A (ja)	2008-08-25	2012-01-12	アンプリミューン、インコーポレーテッド	Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
SG190568A1 (en)	2008-09-26	2013-06-28	Oncomed Pharm Inc	Frizzled-binding agents and uses thereof
EP3263128A3 (en) *	2009-04-14	2018-01-24	GlaxoSmithKline Biologicals S.A.	Compositions for immunising against staphylococcus aureus
EP4015523A1 (en) *	2010-05-05	2022-06-22	New York University	Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof

2011
- 2011-05-05 EP EP21213876.2A patent/EP4015523A1/en active Pending
- 2011-05-05 SI SI201132036T patent/SI3444268T1/sl unknown
- 2011-05-05 DK DK18196549.2T patent/DK3444268T3/da active
- 2011-05-05 KR KR1020187036903A patent/KR102050078B1/ko active Active
- 2011-05-05 MY MYPI2012004840A patent/MY165618A/en unknown
- 2011-05-05 JP JP2013509265A patent/JP6031029B2/ja active Active
- 2011-05-05 PL PL18196549T patent/PL3444268T3/pl unknown
- 2011-05-05 MX MX2012012859A patent/MX2012012859A/es unknown
- 2011-05-05 MX MX2015016666A patent/MX364642B/es unknown
- 2011-05-05 MX MX2019005156A patent/MX386545B/es unknown
- 2011-05-05 CN CN201180033386.0A patent/CN103025352B/zh active Active
- 2011-05-05 KR KR1020127031699A patent/KR101933226B1/ko active Active
- 2011-05-05 RU RU2018100393A patent/RU2677140C1/ru active
- 2011-05-05 EP EP16187485.4A patent/EP3121191B1/en not_active Not-in-force
- 2011-05-05 AU AU2011247989A patent/AU2011247989C1/en active Active
- 2011-05-05 KR KR1020197034641A patent/KR20190133290A/ko not_active Ceased
- 2011-05-05 WO PCT/US2011/035354 patent/WO2011140337A2/en not_active Ceased
- 2011-05-05 ES ES11778343.1T patent/ES2605476T3/es active Active
- 2011-05-05 EP EP11778343.1A patent/EP2566519B1/en active Active
- 2011-05-05 US US13/696,245 patent/US9783582B2/en active Active - Reinstated
- 2011-05-05 EP EP18196549.2A patent/EP3444268B1/en active Active
- 2011-05-05 CA CA3088918A patent/CA3088918A1/en active Pending
- 2011-05-05 HU HUE18196549A patent/HUE058787T2/hu unknown
- 2011-05-05 CA CA2798355A patent/CA2798355C/en active Active
- 2011-05-05 CN CN201710442942.9A patent/CN107286224A/zh active Pending
- 2011-05-05 RU RU2012152086A patent/RU2644237C2/ru active
- 2011-05-05 BR BR112012029521-7A patent/BR112012029521A2/pt not_active Application Discontinuation
- 2011-05-05 US US13/101,525 patent/US8431687B2/en not_active Expired - Fee Related
- 2011-05-05 IL IL274109A patent/IL274109B2/en unknown
- 2011-05-05 HR HRP20220068TT patent/HRP20220068T1/hr unknown
- 2011-05-05 LT LTEP18196549.2T patent/LT3444268T/lt unknown
- 2011-05-05 ES ES18196549T patent/ES2904314T3/es active Active
2012
- 2012-11-05 IL IL222874A patent/IL222874B/en active IP Right Grant
- 2012-11-05 MX MX2021003906A patent/MX2021003906A/es unknown
- 2012-11-09 ZA ZA2012/08455A patent/ZA201208455B/en unknown
2015
- 2015-02-23 AU AU2015200901A patent/AU2015200901B2/en not_active Ceased
2016
- 2016-05-09 ZA ZA2016/03107A patent/ZA201603107B/en unknown
- 2016-10-21 JP JP2016206490A patent/JP6253742B2/ja not_active Expired - Fee Related
- 2016-11-22 AU AU2016262661A patent/AU2016262661B2/en active Active
2017
- 2017-09-08 US US15/699,482 patent/US10316067B2/en active Active
- 2017-11-28 JP JP2017227313A patent/JP6678634B2/ja active Active
2018
- 2018-05-08 ZA ZA2018/02995A patent/ZA201802995B/en unknown
2019
- 2019-05-06 US US16/404,374 patent/US11584782B2/en active Active
- 2019-08-27 AU AU2019222824A patent/AU2019222824A1/en not_active Abandoned
- 2019-12-03 JP JP2019218457A patent/JP7001661B2/ja active Active
2020
- 2020-05-06 ZA ZA2020/02470A patent/ZA202002470B/en unknown
2021
- 2021-09-21 AU AU2021236457A patent/AU2021236457B2/en active Active
2023
- 2023-01-12 US US18/153,727 patent/US20230295248A1/en active Pending

Also Published As

Publication number	Publication date
EP2566519A2 (en)	2013-03-13
IL274109A (en)	2020-06-30
AU2016262661B2 (en)	2019-07-25
RU2012152086A (ru)	2014-06-10
US20190330284A1 (en)	2019-10-31
ZA201802995B (en)	2020-12-23
KR20130060230A (ko)	2013-06-07
US9783582B2 (en)	2017-10-10
WO2011140337A2 (en)	2011-11-10
AU2011247989C1 (en)	2015-05-14
EP4015523A1 (en)	2022-06-22
JP2020055835A (ja)	2020-04-09
MX2012012859A (es)	2013-03-20
JP6253742B2 (ja)	2017-12-27
ES2605476T3 (es)	2017-03-14
MX2019005156A (es)	2019-08-05
CN103025352B (zh)	2017-07-11
SI3444268T1 (sl)	2022-05-31
AU2021236457A1 (en)	2021-10-14
CA2798355A1 (en)	2011-11-10
BR112012029521A2 (pt)	2018-03-06
MX386545B (es)	2025-03-19
EP3444268A1 (en)	2019-02-20
KR20190133290A (ko)	2019-12-02
US20110274693A1 (en)	2011-11-10
WO2011140337A3 (en)	2012-03-15
RU2018146933A (ru)	2020-06-29
JP2017048206A (ja)	2017-03-09
CN107286224A (zh)	2017-10-24
US10316067B2 (en)	2019-06-11
DK3444268T3 (da)	2022-01-31
EP3121191B1 (en)	2018-09-26
EP3121191A1 (en)	2017-01-25
EP3444268B1 (en)	2021-12-15
IL274109B2 (en)	2025-12-01
EP2566519A4 (en)	2014-01-15
MX2021003906A (es)	2021-09-30
CA3088918A1 (en)	2011-11-10
RU2644237C2 (ru)	2018-02-08
IL274109B1 (en)	2025-08-01
RU2677140C1 (ru)	2019-01-15
US20130095115A1 (en)	2013-04-18
AU2015200901A1 (en)	2015-03-12
KR20180137612A (ko)	2018-12-27
AU2011247989B2 (en)	2014-11-27
CA2798355C (en)	2020-09-15
KR102050078B1 (ko)	2019-11-28
ZA201603107B (en)	2018-09-26
US11584782B2 (en)	2023-02-21
HUE058787T2 (hu)	2022-09-28
EP2566519B1 (en)	2016-09-07
US20230295248A1 (en)	2023-09-21
ES2904314T3 (es)	2022-04-04
AU2019222824A1 (en)	2019-09-19
KR101933226B1 (ko)	2018-12-28
IL222874A0 (en)	2012-12-31
CN103025352A (zh)	2013-04-03
AU2016262661A1 (en)	2016-12-08
US8431687B2 (en)	2013-04-30
JP6678634B2 (ja)	2020-04-08
JP2013531620A (ja)	2013-08-08
JP2018076324A (ja)	2018-05-17
MY165618A (en)	2018-04-18
HRP20220068T1 (hr)	2022-04-15
LT3444268T (lt)	2022-04-11
AU2021236457B2 (en)	2024-05-02
ZA201208455B (en)	2016-07-27
JP7001661B2 (ja)	2022-02-21
IL222874B (en)	2020-05-31
ZA202002470B (en)	2022-12-21
US20180099998A1 (en)	2018-04-12
AU2015200901B2 (en)	2016-12-15
MX364642B (es)	2019-05-03
AU2011247989A1 (en)	2012-12-06
JP6031029B2 (ja)	2016-11-24

Publication	Publication Date	Title
PL3444268T3 (pl)	2022-04-19	Leukocydyny staphylococcus aureus, kompozycje terapeutyczne i ich zastosowania
EP2549993A4 (en)	2014-08-06	ANTIMICROBIAL COMPOSITIONS
EP2611310A4 (en)	2014-04-16	ANTIMICROBIAL FORMULATION
EP2941128A4 (en)	2016-11-09	ANTIMICROBIAL COMPOSITIONS
BR112013011844A2 (pt)	2016-07-12	composições pesticidas agrícolas
EP2558132A4 (en)	2015-12-23	ANTIMICROBIAL GEL
EP2725900A4 (en)	2015-08-05	ANTIMICROBIAL COMPOSITION
CO6950492A2 (es)	2014-05-20	Composiciones plaguicidas estables
PT2621277T (pt)	2018-03-07	Composições fungicidas
EP2931050A4 (en)	2016-09-07	BOTANICAL ANTIMICROBIAL COMPOSITIONS
EP2775847A4 (en)	2016-01-13	BOTANICAL ANTIMICROBIAL COMPOSITION
EP2755477A4 (en)	2015-05-06	STABLE POVIDONIODE COMPOSITIONS
EP2934121A4 (en)	2016-07-20	IMPROVED ANTIMICROBIAL COMPOSITIONS
PL3043769T3 (pl)	2023-10-23	Hipertoniczne, terapeutyczne kompozycje przeciwdrobnoustrojowe
EP2755476A4 (en)	2014-12-17	AGRICULTURAL PESTICIDE COMPOSITIONS
BR112013016153A2 (pt)	2017-07-11	composições imunogênicas estáveis de antígenos de staphylococcus aureus
FI20115816L (fi)	2013-02-23	Antimikrobinen ionomeerikoostumus sekä sen käyttösovellukset
EP2627172A4 (en)	2014-11-05	ANTIMICROBIAL COMPOSITION
BR112014005254A2 (pt)	2017-04-04	composições antimicrobianas e usos das mesmas
EP2605654A4 (en)	2014-01-22	ANTIMICROBIAL COMPOSITIONS
IL225495B (en)	2018-07-31	Antimicrobial protein
DK2563375T3 (da)	2014-08-18	Farmaceutiske sammensætninger med phosphonium-antimikrobielle midler
DK2598175T3 (da)	2020-08-03	Radiofarmaceutiske sammensætninger
FI20105517A0 (fi)	2010-05-11	Antimikrobinen koostumus
HK1182925A (en)	2013-12-13	Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof